Cutaneous manifestations of dermatomyositis and their management

Current Rheumatology Reports

Volumn 12, Issue 3, 2010, Pages 192-197

  Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Dermatomyositis; Hydroxychloroquine; Intravenous immune globulin; Methotrexate; Mycophenolate mofetil

Indexed keywords

ANTIESTROGEN; ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYTOTOXIC AGENT; DAPSONE; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MEPACRINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PLACEBO; RAPAMYCIN; RETINOID; RITUXIMAB; TACROLIMUS; THALIDOMIDE;

ALOPECIA; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; IMMUNOHISTOCHEMISTRY; LUPUS ERYTHEMATOSUS; MALIGNANT NEOPLASTIC DISEASE; MUSCLE DISEASE; MYOSITIS; PAPULE; POIKILODERMA; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SKIN BIOPSY; SKIN DISEASE; SKIN MANIFESTATION; TELANGIECTASIA;

DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; EXANTHEMA; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SKIN;

EID: 77953480709     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0100-7     Document Type: Review

References (25)

1. Callen JP, Wortmann RL: Dermatomyositis. Clin Dermatol 2006, 24:363-373.
2. Antiochos BB, Brown LA, Li Z, et al.: Malignancy is associated with dermatomyositis but not polymyositis in northern New England, USA. J Rheumatol 2009, 36:2704-2710. This study demonstrates that the presence of skin disease is an important risk factor for the presence of malignancy.
3. Pachman LM, Abbott K, Sinacore JM, et al.: Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006, 148:247-253.
4. Bendewald MJ, Wetter DA, Li X, Davis MD: Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010, 146:26-30. This study demonstrated that amyopathic dermatomyositis occurs in about 20% of patients with dermatomyositis and that malignancy may occur in these patients as well.
5. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
6. Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407.
7. Dourmishev L, Meffert H, Piazena H: Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed 2004, 20:230-234.
8. Klein RQ, Bangert CA, Costner M, et al.: Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008, 159:887-894.
9. Kasteler JS, Callen JP: Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. JAMA 1994, 272:1939-1941
10. Smith ES, Hallman JR, DeLuca AM, et al.: Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol 2009, 31:61-67. This report demonstrates that although there are subtle histopathologic differences between lupus erythematosus and dermatomyositis, these changes are not useful in distinguishing lupus from dermatomyositis in clinical practice.
11. Magro CM, Crowson AN: The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus. J Cutan Pathol 1997, 24:543-552.
12. Magro CM, Segal JP, Neil Crowson A, Chadwick P: The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol 2009 Nov 4 (Epub ahead of print). This study demonstrates subtle differences between dermatomyositis and lupus erythematosus, but this testing is not likely to be applicable in clinical practice.
13. Sontheimer RD: Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol 2010, 146:76-80.
14. Hill CL, Zhang Y, Sigurgeirsson B, et al.: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357:96-100.
15. Lampropoulos CE, D'Cruz DP: Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis 2005, 64:1376-1377.
16. Woo TY, Callen JP, Voorhees JJ, et al.: Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984, 10:592-600.
17. Ang GC, Werth VP: Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005, 141:855-859.
18. Pelle MT, Callen JP: Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002, 138:1231-1233.
19. Zieglschmid-Adams ME, Pandya A, Cohen SB, Sontheimer RD: The value of methotrexate in dermatomyositis. J Am Acad Dermatol 1998, 38:130-132.
20. Edge JC, Outland JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65-69.
21. Sangle VS, Sangle SR, D'Cruz DP: Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008, 67:723. This is one of several case reports to suggest a place for this agent.
22. Sereda D, Werth VP: Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 2006, 142:70-72.
23. Nadiminti U, Arbiser JL: Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005, 52 (2 Suppl 1): 17-19.
24. Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
25. Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763-767. This report demonstrated moderate effects on the muscle disease but only limited response of the skin disease.